Last updated: March 2, 2026
What Is NDC 00173-0826?
NDC 00173-0826 identifies a specific drug listed under the National Drug Code system. Based on publicly available data, this code corresponds to Cosentyx (secukinumab), a biologic therapy used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.
Current Market Overview
Market Size & Growth
The global biologics market for psoriasis and rheumatologic conditions is projected to reach approximately USD 65 billion by 2028, with a compound annual growth rate (CAGR) of 8-10% from 2023 to 2028.[1]
Within the US, the specialty dermatology market accounts for a significant share, driven by growing prevalence and the chronic nature of conditions treated with drugs like secukinumab.
Key Competitors
Major biologics in the same class:
- Humira (adalimumab)
- Enbrel (etanercept)
- Cosentyx (secukinumab)
- Stelara (ustekinumab)
- Taltz (ixekizumab)
Secukinumab’s market share in 2022 was approximately 20-25% among biologics treating plaque psoriasis.[2]
Adoption & Prescribing Trends
- Increasing diagnosis rates for psoriatic conditions.
- Shift toward biologics due to their efficacy over traditional systemic therapies.
- Payers favor biologics with favorable dosing efficacy and safety profiles.
Price Breakdown & Trends
Current Pricing
- The average wholesale acquisition cost (WAC) for a 150 mg/1.2 mL prefilled syringe/auto-injector is approximately USD 4,600.
- Typical dosing: 150 mg at weeks 0, 1, 2, 3, 4, then every 4 weeks.
Price Trends
- The list price has remained relatively stable since August 2020, following initial pricing of approximately USD 4,300 per dose.
- No significant discounts or biosimilar competition for Secukinumab as of 2023.
- Promised price reductions via biosimilars are pending approval, with potential for USD 1,000-2,000 per dose reduction upon biosimilar entry.
Regulatory Status & Biosimilar Outlook
- No biosimilar approved in the US as of 2023.
- The European Medicines Agency (EMA) approved biosimilars in 2022, with market entry expected in the US by 2024-2025.
- Patent exclusivity extends until 2027; biosimilar competition likely to impact price afterward.
Price Projection (2023-2028)
| Year |
Estimated Cost per Dose (USD) |
Notes |
| 2023 |
4,600 |
Current price, stable; no biosimilar competition. |
| 2024 |
4,600 – 3,800 |
Potential biosimilar entry, modest early discounts. |
| 2025 |
4,600 – 3,200 |
Biosimilar market share increases, discounts grow. |
| 2026 |
4,600 – 2,800 |
Greater biosimilar adoption, price stabilization. |
| 2027 |
4,600 – 2,000 |
Patent expiry, biosimilars predominate. |
| 2028 |
4,600 – 1,800 |
Biosimilar competition intensifies, further discounts. |
Note: These are estimates based on current biosimilar trends, patent landscape, and historical biosimilar pricing patterns.
Market Entry Considerations
- Pricing Dynamics: Initial biosimilar prices typically 30-50% lower than originator.
- Market Penetration: Biosimilar uptake depends on provider acceptance, insurance coverage, and distribution channels.
- Reimbursement Policies: Payers' cost-sharing adjustments could accelerate biosimilar adoption and further reduce net costs.
Key Takeaways
- NDC 00173-0826 (Cosentyx) commands a high price point (~USD 4,600 per dose) with stable current pricing.
- The biologics market for psoriasis and related indications is growing rapidly worldwide.
- Biosimilar competition is imminent, likely reducing prices significantly starting in 2024.
- Market share shifts will depend on biosimilar approval, insurance policies, and physician prescribing habits.
- Projected cost decline by 2028 could reach approximately 60-70% below current pricing.
FAQs
What factors influence the future price of secukinumab?
Patent expiration, biosimilar approvals, market competition, payer policies, and manufacturing costs.
How soon will biosimilars impact secukinumab’s pricing?
Biosimilars are expected in the US between 2024 and 2025, significantly influencing pricing.
Are there generic alternatives to secukinumab?
No; as a biologic, secukinumab has no true generics. Biosimilars will replace it as the primary cost-lowering alternative.
How does secukinumab compare to competitors in price and efficacy?
It stands competitively, with similar efficacy to other IL-17 inhibitors like ixekizumab and brodalumab, but has a higher current list price.
What are the risks for investors or manufacturers related to secukinumab pricing?
Patent expiry, biosimilar market entry, and payer reimbursement policies pose potential risks to profitability.
Sources:
[1] MarketsandMarkets. (2022). Biologics Market by Application, Type, and Region.
[2] IQVIA. (2022). Top Treatment Trends in Dermatology.
